- Key Takeaways
- A Fundamentally Different Commercial Model
- Patient Community Relationships
- Non-Standard Regulatory and Evidence Paths
- Finding Candidates Who Fit
- What This Looks Like in Practice
- The Mistake Employers Keep Making
- Large-Market Pharma vs Rare Disease
- The Bottom Line
- Related Reading
- Frequently Asked Questions
Drawing on our executive search practice, we put this together to give employers a grounded, practical view they can act on. Rare disease and orphan drug companies operate under conditions that make executive recruiting genuinely distinctive: tiny patient populations, close relationships with patient communities, unusual regulatory pathways, and commercial models built around finding and supporting very small numbers of patients. Executives from large-market pharmaceutical backgrounds frequently misjudge how different this is, and the mismatch is one of the more common recruiting failures in the sector.
Key Takeaways
- Rare disease commercial models differ fundamentally from large-market pharma.
- Patient identification and support replace conventional promotion.
- Patient advocacy relationships are central and require genuine commitment.
- Regulatory pathways and evidence approaches are often non-standard.
- Large-market pharma experience frequently misfits without adaptation.
A Fundamentally Different Commercial Model
In rare disease, commercial success is not about share of a large prescriber base but about finding patients who are often undiagnosed, supporting a small number of treating physicians, and managing complex reimbursement for high-cost therapies patient by patient. Sales organisations are small and deeply technical; patient services and case management are central rather than peripheral. An executive whose experience is in building large field forces for primary care products is operating in a genuinely different discipline, and the assumption that commercial leadership transfers is where many rare disease hires go wrong.
Patient Community Relationships
Rare disease companies work closely with patient advocacy organisations that are often small, deeply informed, and highly invested. These relationships influence trial recruitment, regulatory engagement, and reputation, and they require genuine, sustained commitment rather than transactional engagement. Executives who treat advocacy as a communications function, or who approach these communities instrumentally, damage relationships that are difficult to repair and that the company depends on. Assess candidates for authentic engagement with patient communities, since in this sector it is a practical business capability rather than a soft consideration.
Non-Standard Regulatory and Evidence Paths
Small populations make conventional trial designs difficult or impossible, and rare disease development frequently relies on natural history studies, single-arm trials, surrogate endpoints, adaptive designs, and close regulatory dialogue. Leaders in development, regulatory, and medical roles need comfort with this ambiguity and experience constructing evidence arguments where a large randomised trial is not feasible. Candidates whose experience is entirely with conventional large-population development often underestimate how much judgment and regulatory engagement rare disease programmes require.
Finding Candidates Who Fit
The pool with genuine rare disease experience is small, so companies usually must consider adaptable candidates from adjacent contexts. The characteristics that predict success are a genuine interest in the disease area and patient community, comfort with small-scale and ambiguity, willingness to work hands-on, and intellectual humility about what they do not know. Screening for these is more useful than screening for large-company pedigree. Candidates who articulate why this specific rare disease context interests them, beyond career progression, are usually the ones who adapt well.
What This Looks Like in Practice
A rare disease company assesses candidates for understanding of the sector’s distinctive commercial model, authentic engagement with patient communities, comfort with non-standard development and evidence approaches, and hands-on adaptability, prioritising these over large-market pharmaceutical pedigree when drawing from adjacent talent pools.
The Mistake Employers Keep Making
The most common mistake is hiring a commercial leader from a large-market pharmaceutical background on the strength of their track record, assuming rare disease is simply a smaller version of the same job. It is not: patient identification, case-level reimbursement, and community relationships replace conventional promotion. The company mistakes scale-down for a different discipline, and the executive applies a playbook that does not fit.
Large-Market Pharma vs Rare Disease
| Dimension | Large Market | Rare Disease |
|---|---|---|
| Commercial model | Broad prescriber promotion | Patient finding and case support |
| Field organisation | Large, territory-based | Small, deeply technical |
| Patient services | Supporting function | Central to the model |
| Advocacy relationships | One stakeholder among many | Business-critical |
| Development approach | Conventional randomised trials | Often non-standard designs |
The Bottom Line
Rare disease and orphan drug companies operate a fundamentally different commercial and development model, so recruit for genuine understanding of patient identification, community relationships, and non-standard evidence approaches, and prioritise adaptability and authentic interest over large-market pharmaceutical pedigree. Hire for the specific demands of the situation, and the rest of the leadership equation gets easier.
Related Reading
For more, see How to Recruit a Chief Medical Officer for a Pharma Company, What Makes a Great VP of Market Access in Pharma, Building an Executive Team for a Pre-Commercial Biotech.
Frequently Asked Questions
- Q: How does rare disease commercial work differ?
- A: Success depends on finding often-undiagnosed patients, supporting a small number of treating physicians, and managing case-level reimbursement, rather than promoting to a large prescriber base.
- Q: Why do patient advocacy relationships matter so much?
- A: Because these organisations influence trial recruitment, regulatory engagement, and reputation, and they require genuine sustained commitment rather than transactional or instrumental engagement.
- Q: What is different about rare disease development?
- A: Small populations make conventional trials difficult, so programmes often rely on natural history studies, single-arm designs, surrogate endpoints, and close regulatory dialogue.
- Q: Can large-pharma executives succeed in rare disease?
- A: Some can, but it requires genuine adaptation; the commercial model, scale, and evidence approaches differ enough that assuming transferability is a common cause of failure.
- Q: What predicts success when hiring from adjacent pools?
- A: Genuine interest in the disease area and patient community, comfort with ambiguity and small scale, hands-on willingness, and intellectual humility about what they do not know.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
